SG155049A1 - Process for the manufacture of valsartan - Google Patents

Process for the manufacture of valsartan

Info

Publication number
SG155049A1
SG155049A1 SG200702272-6A SG2007022726A SG155049A1 SG 155049 A1 SG155049 A1 SG 155049A1 SG 2007022726 A SG2007022726 A SG 2007022726A SG 155049 A1 SG155049 A1 SG 155049A1
Authority
SG
Singapore
Prior art keywords
manufacture
valsartan
receptor antagonist
arb
salts
Prior art date
Application number
SG200702272-6A
Other languages
English (en)
Inventor
Donatienne Denni-Dischert
Hans Hirt
Dan Neville
Gottfried Sedelmeier
Anita Schnyder
Nadine Derrien
Daniel Kaufmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG155049(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG155049A1 publication Critical patent/SG155049A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
SG200702272-6A 2002-09-23 2003-09-22 Process for the manufacture of valsartan SG155049A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0222056.4A GB0222056D0 (en) 2002-09-23 2002-09-23 Process for the manufacture of organic compounds

Publications (1)

Publication Number Publication Date
SG155049A1 true SG155049A1 (en) 2009-09-30

Family

ID=9944606

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200702272-6A SG155049A1 (en) 2002-09-23 2003-09-22 Process for the manufacture of valsartan

Country Status (30)

Country Link
US (3) US20060069268A1 (fr)
EP (2) EP1546122B8 (fr)
JP (2) JP4787498B2 (fr)
KR (2) KR20050057529A (fr)
CN (2) CN101153027B (fr)
AR (1) AR041360A1 (fr)
AU (1) AU2003270241B2 (fr)
BR (1) BR0314132A (fr)
CA (1) CA2502629A1 (fr)
CY (1) CY1107878T1 (fr)
DE (1) DE60317690T2 (fr)
DK (1) DK1546122T3 (fr)
EC (2) ECSP055695A (fr)
ES (1) ES2295623T3 (fr)
GB (1) GB0222056D0 (fr)
HK (1) HK1079771A1 (fr)
IL (1) IL167426A (fr)
MX (1) MXPA05003140A (fr)
MY (1) MY138618A (fr)
NO (2) NO20051970L (fr)
NZ (2) NZ566863A (fr)
PE (2) PE20091387A1 (fr)
PL (1) PL374862A1 (fr)
PT (1) PT1546122E (fr)
RU (2) RU2348619C2 (fr)
SG (1) SG155049A1 (fr)
SI (1) SI1546122T1 (fr)
TW (2) TWI329106B (fr)
WO (1) WO2004026847A1 (fr)
ZA (1) ZA200502159B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
CA2519490A1 (fr) * 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd Formes polymorphes de valsartan
EP1556363A2 (fr) * 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Procede de preparation du valsartan et de ses intermediaires
US7378531B2 (en) 2003-04-21 2008-05-27 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1661891A1 (fr) * 2004-11-30 2006-05-31 KRKA, D.D., Novo Mesto Procédé de prépartion de valsartan
GB0514206D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
ES2288376B1 (es) * 2005-10-20 2008-11-01 Inke, S.A. Procedimiento para la obtencion de intermedios utiles en la obtencion de un compuesto farmaceuticamente activo.
WO2007057919A2 (fr) * 2005-10-25 2007-05-24 Alembic Limited Procede ameliore pour la preparation de (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
WO2008004110A2 (fr) * 2006-07-03 2008-01-10 Aurobindo Pharma Limited Procédé amélioré de préparation d'un antagoniste de l'angiotensine ii
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
CN101200455B (zh) * 2007-09-29 2010-08-18 泰兴市江神化工有限公司 沙坦类治疗高血压药物主环5-(4'-甲酰基联苯-2-基)-1h-四氮唑的制备方法
US7943794B2 (en) * 2008-02-13 2011-05-17 Ranbaxy Laboratories Limited Processes for the preparation of intermediates of valsartan
KR101012135B1 (ko) * 2008-12-18 2011-02-07 주식회사 대희화학 발사르탄 메틸 에스테르의 제조방법
EP2316821A1 (fr) 2009-10-27 2011-05-04 Novartis AG Procédé pour la fabrication de composés organiques
CA2806657A1 (fr) * 2010-08-03 2012-02-09 Novartis Ag Valsartan hautement cristallin
CN102351804B (zh) * 2011-09-30 2013-07-31 浙江新赛科药业有限公司 一种缬沙坦消旋体的回收方法
CN103554047A (zh) * 2013-10-11 2014-02-05 镇江市高等专科学校 制备缬沙坦的方法
CN103923028B (zh) * 2014-05-04 2017-05-24 青岛雪洁助剂有限公司 一种缬沙坦甲酯的制备方法
CN104072433A (zh) * 2014-07-16 2014-10-01 南京正大天晴制药有限公司 一种缬沙坦的水解杂质化合物及其制备方法、检测方法和用途
CN104151199A (zh) * 2014-08-13 2014-11-19 苏州卫生职业技术学院 一种缬沙坦的合成方法
CN104844476B (zh) * 2015-04-03 2016-08-24 李凌 一种医药中间体联苯类化合物的合成方法
CN112014479A (zh) * 2019-05-28 2020-12-01 珠海润都制药股份有限公司 一种缬沙坦中正戊酰氯的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0443983T3 (da) * 1990-02-19 1996-03-18 Ciba Geigy Ag Acrylforbindelser
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
FR2688503B1 (fr) * 1992-03-16 1994-05-06 Synthelabo Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle].
EP0550313A1 (fr) * 1991-12-30 1993-07-07 Synthelabo Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
JPH08165292A (ja) * 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
US5412102A (en) * 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
WO1996009301A1 (fr) * 1994-09-20 1996-03-28 Wakunaga Seiyaku Kabushiki Kaisha Procede de production d'un derive de n-biphenylmethylthiadiazoline ou un sel de celui-ci et son intermediaire de production
JPH11507625A (ja) * 1995-06-07 1999-07-06 アメリカン・ホーム・プロダクツ・コーポレイション ビフェニル誘導体の製造方法
CN1137887C (zh) * 2000-04-07 2004-02-11 常州四药制药有限公司 一种合成缬沙坦的改进方法
IL153882A0 (en) * 2000-07-19 2003-07-31 Novartis Ag Valsartan salts
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds

Also Published As

Publication number Publication date
US20090111995A1 (en) 2009-04-30
NO20110856L (no) 2005-06-16
PE20091387A1 (es) 2009-10-13
NO20051970L (no) 2005-06-16
KR20050057529A (ko) 2005-06-16
RU2348619C2 (ru) 2009-03-10
CN1688556A (zh) 2005-10-26
DE60317690T2 (de) 2008-10-30
US20100249429A1 (en) 2010-09-30
TWI329106B (en) 2010-08-21
US20060069268A1 (en) 2006-03-30
EP1546122A1 (fr) 2005-06-29
JP2010254709A (ja) 2010-11-11
IL167426A (en) 2010-11-30
NZ538927A (en) 2008-05-30
JP2006502178A (ja) 2006-01-19
TW200413337A (en) 2004-08-01
MY138618A (en) 2009-07-31
CN101153027B (zh) 2010-08-18
JP4787498B2 (ja) 2011-10-05
NZ566863A (en) 2009-08-28
BR0314132A (pt) 2005-06-28
AR041360A1 (es) 2005-05-11
EP1546122B1 (fr) 2007-11-21
EP1878729A1 (fr) 2008-01-16
DE60317690D1 (de) 2008-01-03
EP1546122B8 (fr) 2008-05-28
AU2003270241B2 (en) 2007-08-23
CA2502629A1 (fr) 2004-04-01
DK1546122T3 (da) 2008-03-03
GB0222056D0 (en) 2002-10-30
RU2412173C2 (ru) 2011-02-20
MXPA05003140A (es) 2005-06-22
PE20050088A1 (es) 2005-02-21
CN101153027A (zh) 2008-04-02
PL374862A1 (en) 2005-11-14
RU2005112444A (ru) 2006-01-20
ZA200502159B (en) 2005-09-21
SI1546122T1 (sl) 2008-04-30
ECSP105695A (es) 2010-03-31
HK1079771A1 (en) 2006-04-13
PT1546122E (pt) 2008-02-14
KR20110015703A (ko) 2011-02-16
AU2003270241A1 (en) 2004-04-08
TWI338003B (en) 2011-03-01
WO2004026847A1 (fr) 2004-04-01
ECSP055695A (es) 2005-05-30
CN100357279C (zh) 2007-12-26
ES2295623T3 (es) 2008-04-16
RU2008133680A (ru) 2010-02-27
CY1107878T1 (el) 2013-06-19
TW201016673A (en) 2010-05-01

Similar Documents

Publication Publication Date Title
SG155049A1 (en) Process for the manufacture of valsartan
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
TNSN05105A1 (en) Novel bicyclic inhibitors of hormone sensitive lipase
TNSN07195A1 (en) Potentiators of glutamate receptors
DE60239428D1 (fr)
MY149856A (en) Therapeutic agent for mesothelioma
TW200624426A (en) BACE inhibitors
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
MXPA04010625A (es) Antagonista de receptor de taquicinina.
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
TW200640912A (en) Novel processes for the preparation of a 2H-chromene
TW200619205A (en) A method for preparing irbesartan and intermediates thereof
AU2003274307A1 (en) 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
TW200621756A (en) Method for manufacturing enantiomeric imidazole compounds
HK1079513A1 (en) Process for preparing intermediates
MY139159A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
HK1094575A1 (en) A process for the preparation of phenyltetrazole derivatives
SG149005A1 (en) Process for the preparation of thiazolopyrimidines
MY139348A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
MY136288A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
WO2005054175A3 (fr) Nouveau procede pour la preparation de derives nitro-oxy de paracetamol
AU2003285428A1 (en) Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
WO2007017469A3 (fr) Procede de preparation d'un antagoniste des recepteurs de l'angiotensine ii
AU2003274087A1 (en) Method for identifying agonists or antagonists for the gpr45-like/gpr63 receptor